Atea Pharmaceuticals

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is currently focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV, and in July 2026, the company announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV. In July 2026, Atea announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.

1. Home - Atea Pharmaceuticals
2. About Us - Atea Pharmaceuticals
3. Hepatitis C - Atea Pharmaceuticals
4. Careers - Atea Pharmaceuticals
5. Atea Pharmaceuticals (United States)